Initial Treatment News Today

WAYNE, Pa., May 07, 2024 -- Teleflex Incorporated , a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American Urological Association...

Highlights include two head-to-head randomized clinical trials data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia -Additional studies examine...

Compliance Corner: Nevada Duties of Health Care Providers Required to File Claims | Workerscompensation.com

Most newly treated patients with type 2 diabetes exhibit suboptimal medication persistence, which is associated with higher risk of hospitalization and increased medical costs.

Compliance Corner: Nevada Posters | Workerscompensation.com

Civil servants have been told to work from home after offices used by government departments including a health agency became infested with bedbugs.

(Reuters) -Gilead Sciences said on Monday its drug, Trodelvy, failed to significantly improve survival for previously treated patients with advanced non-small cell lung cancer (NSCLC) in a late-stage study, sending its shares down more than 10%. The California-based drugmaker was testing Trodelvy, which belongs to a class of treatments known as antibody drug conjugates, in patients with both squamous and non-squamous NSCLC - the most common type of lung cancer. Roughly 230,000 adults in the Un...

/PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its PulseSelect™ Pulsed Field Ablation (PFA) System...

- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company's LIMBER studies evaluating ruxolitinib

(NewsUSA) - Pulse Check: 3 Things You May Not Know About the Most Common Heart Rhythm Disorder